ERASCA INC

Company Overview

Erasca, Inc. (ERAS) is a clinical‑stage precision oncology company focused on therapies for cancers driven by RAS/MAPK pathway alterations. The company follows a modality‑agnostic, portfolio‑based strategy centered on MAPKlamp combinations (e.g., naporafenib + trametinib), direct RAS targeting, and resistance‑route blockade, with a Phase 3 pivotal SEACRAFT‑12 trial underway for naporafenib+trametinib and INDs filed/cleared for two pan‑RAS programs. Erasca operates as an R&D‑centric, virtual manufacturing organization that outsources GMP supply while retaining in‑house discovery and clinical development, has no product revenue, and finances operations largely via equity raises and licensing arrangements.

Executive Compensation Practices

Given Erasca’s clinical‑stage profile and lack of product revenue, executive pay is likely weighted heavily toward equity‑based incentives (stock options/RSUs) and milestone‑linked awards to align management with long‑dated clinical and regulatory outcomes (e.g., SEACRAFT readouts, IND/Phase‑1 milestones). The MD&A explicitly calls out stock‑based compensation and Black‑Scholes inputs as a critical accounting estimate, so option valuation assumptions materially affect reported G&A and quarterly EPS impacts; in‑process R&D license payments and milestone obligations also drive unusual one‑time charges that can mask cash vs. non‑cash compensation trends. As the company shifts resources to later‑stage development and contemplates a U.S. commercial build if approved, compensation mixes may evolve to include retention bonuses, performance‑based long‑term incentives tied to regulatory/commercial milestones, and market‑competitive packages to retain scientific leadership.

Insider Trading Considerations

Insider trading at ERAS will likely cluster around binary, high‑impact events: pivotal trial readouts (SEACRAFT stages), IND clearances/Phase‑1 data, licensing/partnering announcements, and financing rounds — all of which create material non‑public information. Executives are subject to Section 16 reporting and will often use 10b5‑1 plans or adhere to formal blackout windows around clinical data and regulatory interactions; reliance on third‑party manufacturing and partner negotiations further increases the frequency of material events that should trigger trading restrictions. Investors should watch for patterns of insider sales following large equity raises (dilution risk), the timing of option exercises relative to milestone announcements, and any Form 4 filings clustered near strategic partnership, IND, or FDA communications.